Differences in cNOS/iNOS Activity during Resistance to Trypanosoma cruzi Infection in 5-Lipoxygenase Knockout Mice.

Publisher: Wiley Country of Publication: United States NLM ID: 9209001 Publication Model: eCollection Cited Medium: Internet ISSN: 1466-1861 (Electronic) Linking ISSN: 09629351 NLM ISO Abbreviation: Mediators Inflamm Subsets: MEDLINE

Publication: 2023- : Hoboken, NJ : Wiley
Original Publication: Oxford, UK : Rapid Communications of Oxford Ltd., c1992-

Arachidonate 5-Lipoxygenase/*blood ; Chagas Disease/*blood ; Chagas Disease/*enzymology; Animals ; Antioxidants/metabolism ; Cytokines/blood ; Mice ; Mice, Knockout ; Nitric Oxide/blood ; Nitric Oxide Synthase Type II/blood ; Trypanosoma cruzi/pathogenicity

Infection with the protozoan Trypanosoma cruzi causes Chagas disease and consequently leads to severe inflammatory heart condition; however, the mechanisms driving this inflammatory response have not been completely elucidated. Nitric oxide (NO) is a key mediator of parasite killing in T. cruzi -infected mice, and previous studies have suggested that leukotrienes (LTs) essentially regulate the NO activity in the heart. We used infected 5-lipoxygenase-deficient mice (5-LO ^-/- ) to explore the participation of nitric oxide synthase isoforms, inducible (iNOS) and constitutive (cNOS), in heart injury, cytokine profile, and oxidative stress during the early stage of T. cruzi infection. Our evidence suggests that the cNOS of the host is involved in the resistance of 5-LO ^-/- mice during T. cruzi infection. iNOS inhibition generated a remarkable increase in T. cruzi infection in the blood and heart of mice, whereas cNOS inhibition reduced cardiac parasitism (amastigote nests). Furthermore, this inhibition associates with a higher IFN- γ production and lower lipid peroxidation status. These data provide a better understanding about the influence of NO-interfering therapies for the inflammatory response toward T. cruzi infection.
Competing Interests: The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.
(Copyright © 2019 Carolina Panis et al.)

Microbes Infect. 2010 Aug;12(8-9):587-97. (PMID: 20381637)
FEMS Immunol Med Microbiol. 2008 Jan;52(1):47-58. (PMID: 18031539)
Clin Chim Acta. 1996 Nov 29;255(2):107-17. (PMID: 8937754)
Infect Immun. 1999 Aug;67(8):3864-71. (PMID: 10417150)
Mediators Inflamm. 2004 Aug;13(4):235-40. (PMID: 15545053)
FEMS Immunol Med Microbiol. 2004 May 1;41(1):69-77. (PMID: 15094169)
Infect Immun. 2004 Jan;72(1):359-63. (PMID: 14688116)
Front Microbiol. 2016 Mar 23;7:348. (PMID: 27047464)
Infect Immun. 2002 Aug;70(8):4247-53. (PMID: 12117933)
N Engl J Med. 2007 Nov 1;357(18):1841-54. (PMID: 17978293)
Clin Exp Immunol. 2002 Jun;128(3):421-8. (PMID: 12067296)
PLoS Negl Trop Dis. 2014 Oct 02;8(10):e3207. (PMID: 25275456)
Life Sci. 2007 Sep 29;81(16):1301-8. (PMID: 17916368)
Acta Trop. 2016 May;157:42-53. (PMID: 26827742)
Mem Inst Oswaldo Cruz. 2009 Nov;104(7):1051-4. (PMID: 20027478)
Blood. 1999 Feb 15;93(4):1399-405. (PMID: 9949184)
J Exp Med. 1994 Sep 1;180(3):977-84. (PMID: 7520478)
Immunol Lett. 2009 Mar 24;123(1):38-45. (PMID: 19428550)
Lancet Infect Dis. 2015 Nov;15(11):1347-56. (PMID: 26231478)
Breast Cancer Res Treat. 2012 May;133(1):89-97. (PMID: 21811816)
Adv Parasitol. 2011;76:1-31. (PMID: 21884885)
J Clin Invest. 1998 Jun 15;101(12):2780-9. (PMID: 9637712)
J Immunol. 1985 Mar;134(3):1989-93. (PMID: 2857187)
Front Biosci. 1997 Jan 01;2:d12-26. (PMID: 9159205)
Mediators Inflamm. 2014;2014:893634. (PMID: 25165415)
Scand J Immunol. 2004 Oct;60(4):412-20. (PMID: 15379866)
Int J Parasitol. 2002 Jun 15;32(7):897-905. (PMID: 12062561)
Am J Pathol. 2006 Jan;168(1):349-62. (PMID: 16400036)
Curr Infect Dis Rep. 2012 Jun;14(3):263-74. (PMID: 22477037)
Circ Res. 1996 Sep;79(3):363-80. (PMID: 8781470)
Exp Parasitol. 2011 Jan;127(1):58-65. (PMID: 20599987)
PLoS Negl Trop Dis. 2015 Aug 25;9(8):e0004025. (PMID: 26305786)
Immunology. 2008 Feb;123(2):250-62. (PMID: 17894798)
Biochemistry. 1999 Sep 21;38(38):12505-13. (PMID: 10493821)
Rev Inst Med Trop Sao Paulo. 1962 Nov-Dec;4:389-96. (PMID: 14015230)
Int J Parasitol. 2003 Mar;33(3):293-9. (PMID: 12670514)
Infect Immun. 1994 Nov;62(11):5177-82. (PMID: 7523307)
J Immunol. 2006 Sep 1;177(5):3201-8. (PMID: 16920959)
Parasitology. 2014 Jun;141(7):904-13. (PMID: 24552620)
Immunology. 2005 Dec;116(4):418-28. (PMID: 16313356)
J Biol Chem. 1992 Mar 15;267(8):5317-23. (PMID: 1312087)
Am J Trop Med Hyg. 2009 May;80(5):782-7. (PMID: 19407124)
Parasite Immunol. 1993 Dec;15(12):693-9. (PMID: 7877845)
Antimicrob Agents Chemother. 2014 Oct;58(10):6157-64. (PMID: 25092706)
Am J Pathol. 1998 Apr;152(4):925-34. (PMID: 9546353)
J Leukoc Biol. 1995 Aug;58(2):217-24. (PMID: 7543922)
Free Radic Biol Med. 1991;10(2):93-100. (PMID: 1849867)
Circulation. 2000 Dec 12;102(24):3003-8. (PMID: 11113053)
PLoS Negl Trop Dis. 2012;6(5):e1644. (PMID: 22590660)
Adv Pharmacol Sci. 2015;2015:298792. (PMID: 26692194)
Front Biosci. 2003 May 01;8:s314-25. (PMID: 12877141)
Infect Immun. 2004 Jul;72(7):4081-9. (PMID: 15213153)
Eur J Pharmacol. 1993 Mar 16;233(1):119-25. (PMID: 7682510)
Nature. 1994 Nov 10;372(6502):179-82. (PMID: 7969451)
Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:236-45. (PMID: 19753479)
J Mol Cell Cardiol. 2008 Nov;45(5):625-32. (PMID: 18722380)
Eur J Immunol. 1992 Feb;22(2):301-7. (PMID: 1537373)

0 (Antioxidants)
0 (Cytokines)
31C4KY9ESH (Nitric Oxide)
EC 1.13.11.34 (Arachidonate 5-Lipoxygenase)
EC 1.14.13.39 (Nitric Oxide Synthase Type II)

Date Created: 20191128 Date Completed: 20200504 Latest Revision: 20200505

20250114

PMC6854994

10.1155/2019/5091630

31772504